Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Inclusion Criteria:

1. Healthy, post-menarcheal and premenopausal women at risk of pregnancy who are atleast 16 years of age.

2. Desires to avoid pregnancy, is seeking to use hormonal contraception for at least 1year.

3. Has negative UPT results at screening and at enrollment visits.

4. Has normal, regular menstrual cycles that are between 21 and 35 days in durationover the last 6 months.

5. Engages in regular heterosexual vaginal intercourse (at least once per cycle), witha partner who is not known to be sub fertile or infertile.

6. Agrees not to use other contraceptives or other methodology to prevent pregnancyduring the study.

7. Able to understand and voluntarily provide written informed consent or assent (ifthe participant is adolescent prior to undergoing any trial related procedure) toparticipate in the study.

Exclusion Criteria:

1. Known or suspected pregnancy or planning pregnancy during next 12 months.

2. Participants with known hypersensitivity or intolerance to progestins, or anycomponents of the progestin patch.

3. History or presence of dermal sensitivity to medicated patches or to topicalapplications including bandages, surgical tape.

4. Known infertility (current or known history) or history of sterilization in eitherpartner.

5. Received injectable hormonal contraceptive therapy within 10 months of studyenrollment.

6. Current use of hormonal contraceptive implants.

7. Has non-hormonal or hormonal intrauterine device (IUD) in place; or has had a recentIUD removal without one spontaneous menses after removal prior to the date ofenrollment.

8. Recent surgical or medical abortion, miscarriage, ectopic pregnancy, or vaginal orcesarean delivery.

9. Participants lactating at the time of screening into the study or has occurrence ofless than 3 regular menstrual cycles after cessation of lactation.

10. Anticipates routine use of condoms or any other form of back-up contraception forprotection from sexually transmitted infections during the study or for emergencycontraception.

11. Participants having a known contraindication to progestin-only contraception.

12. Known or suspected progestin sensitive malignant or premalignant conditionsincluding but not limited to carcinoma of endometrium, ovary, or fallopian tubes.

13. Skin abnormality (e.g., tattoo or scar) at all possible application sites.

14. Long-term treatment with drugs or herbal products that are moderate/strong inducersor inhibitors of CYP3A4.

15. Has uncontrolled thyroid disorder (thyrotoxicosis or myxedema).

16. Has diagnosis of hereditary angioedema.

17. Participants with abnormal significant liver function tests as measured by liverfunction tests

18. Has a significantly abnormal cervical cancer screening test.

19. Participants with chlamydial or gonorrheal infection at screening.

20. Has unexplained vaginal bleeding within the past 6 months or any abnormal bleedingwhich is expected to recur during the study.